How glioblastoma changes across the tumor and over time during treatment
Official title: Dissecting spatiotemporal heterogeneity of glioblastoma evolution under therapy
Funded at Translational Genomics Research Inst · NIH-11457140 · Data updated 2026-11-12
This work maps how glioblastoma tumors shift their cell types and interactions during and after treatment to find weaknesses that could help people with recurrent GBM.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Translational Genomics Research Inst NIH-funded |
| Lab location | 1 site (Phoenix, United States) |
| Project start | February 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $248,999 |
| NIH project number | 4R00CA286730-03 |
| Project ID | NIH-11457140 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates would be people with IDH wild-type glioblastoma who have tumor tissue available from initial surgery and from a later recurrence or consent to provide samples during care at participating centers.
✕Less likely to help
People without glioblastoma, those with tumors that are not IDH wild-type, or patients seeking an immediate therapeutic benefit are unlikely to gain direct benefit from this research.
What this research studies
From my perspective as a patient, the team will study tumor tissue taken at first surgery and again if the tumor comes back to see how cancer cells and nearby brain cells change over time and across different tumor areas. They will use detailed molecular tools like single-nucleus RNA sequencing and proteogenomics to make cell-by-cell and protein-level maps of the tumor ecosystem. The researchers are especially looking at a neuronal-like state of tumor cells and how connections with normal neurons may help tumors invade and resist therapy. By comparing matched primary and recurrent samples, they hope to spot genetic and non-genetic changes that open up new treatment possibilities.
Why it matters
Potential benefit: If successful, this work could point to new molecular targets or strategies to better treat or prevent recurrent glioblastoma.
How similar studies have gone: Prior studies in cancer neuroscience have shown that neuron–glioma interactions matter for tumor growth, but translating those findings into patient treatments is still early and largely experimental.
Where this research is happening
-
Translational Genomics Research Inst
Phoenix, United States Active
Researchers
- Principal investigator: Migliozzi, Simona — Translational Genomics Research Inst
- Study coordinator: Migliozzi, Simona
Related research
Other NIH-funded projects on the same topics.
-
Small molecules to block Slit2/ROBO in glioblastoma
A study to test small molecule drugs that block Slit2/ROBO signals to help treat glioblastoma in patients.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
Small-molecule and biologic treatments for glioblastoma using targeted brain delivery
A new approach aims to use FPS-ZM1 to shrink brain swelling and support immunotherapy for glioblastoma, potentially helping patients recover after surgery.
-
Targeted therapies for glioblastoma in adults and kids
A large NIH program is exploring new brain cancer therapies, including drugs that reach the brain and work against glioblastoma in both children and adults.
-
6-thio-2'-deoxyguanosine for glioblastoma: a new approach to target tumors before surgery
A trial tests a novel drug given before glioblastoma surgery to see how it behaves in the body and within the tumor, and to learn how it affects cancer cells and the immune environment.
-
CD38-Driven Changes in Brain Tumor Metabolism and Immunity in Glioblastoma
A patient-facing look at how scientists plan to study how glioblastoma grows by changing its metabolism and dampening the immune response, with potential targets to help treatment in the future.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.